| Log in
Photo Credit: Reuters

Gland Pharma looks to revise Fosun deal; Rosatom eyes Inox’s wind turbine biz

21 August, 2017

The shareholders of Gland Pharma Ltd, including buyout firm KKR and Co., are now considering selling up to 74% under the automatic approval route to China’s Fosun International, says a Mint report citing two people aware of the development.

Both sides have extended the exclusivity period to conclude the deal to September-end, the report adds.

The development comes after Gland Pharma failed to secure government approval for an 86% stake sale. In July 2016, Shanghai Fosun Pharmaceutical Ltd had struck a deal to buy 86% in Gland Pharma Ltd for $1.26 billion.

VCCircle was first to report that the border standoff between the two countries may derail the deal.

The transaction has been awaiting the Cabinet Committee of Economic Affairs’ (CCEA) approval since April. The CCEA, chaired by Prime Minister Narendra Modi, clears all high-value foreign direct investment transactions.

Russia’s Rosatom State Atomic Energy Corporation is exploring an investment in Inox Group’s wind turbine manufacturing business, says a Mint report citing people familiar with the matter.

Rosatom is exploring the investment to build a manufacturing presence in India’s wind energy space, the report adds.

In March, JPMorgan-backed Leap Green Energy Pvt. Ltd agreed to acquire the entire operational wind power capacity of Inox Renewables Ltd. The total generation capacity of Inox Renewables is about 260MW.

Inox Renewables is part of the Inox Group and a wholly-owned subsidiary of Gujarat Fluorochemicals Ltd, the group’s flagship company.

At least four entities, including two leading medical devices makers and two private equity investors, have submitted bids for a majority stake in Bangalore-based Healthium Medtech Pvt. Ltd, says a Mint report.

Private equity firm TPG Capital, which holds a 73% stake in the company through TPG Growth, is planning to sell a controlling stake in the medical products maker at a valuation of $500 million, the report says. VCCircle first reported last month that TPG was looking at a strategic buyer rather than a financial investor.

Medical devices makers Boston Scientific Corp. of the US and Ireland’s Covidien Medtronic, and private equity funds Carlyle and Advent International submitted non-binding bids last week, the report adds.

Healthium Medtech Pvt Ltd was earlier known as Sutures India Pvt. Ltd.

Private equity firm Everstone Capital is looking at selling its 45% stake in JS Hospitality Services Pvt. Ltd, the company that runs the Pind Balluchi chain of restaurants, says a report in The Economic Times.

The fund is expected to generate returns 2-2.5 times its five-year-old investment. The initial work on the exit has just begun, and the fund will reach out to prospective financial and strategic partners for the stake sale, the report adds.

According to VCCEdge, the data research platform of VCCircle, Everstone picked up 49% in JS Hospitality for $21.21 million in January 2012. As of March 2016, it held 49% in JS Hospitality Services through F&B Asia Ventures Pte Ltd.

F&B Asia Ventures is a pan-Asian food and beverage business platform promoted and controlled by private equity firm Everstone Capital. The various assets under F&B Asia include Pind Balluchi, Harry’s, The Disgruntled Chef, besides local franchise of Domino’s in Indonesia and Burger King in India and Indonesia, among others.

Like this report? Sign up for our daily newsletter to get our top reports.


Leave Your Comment
Fosun extends deadline to buy Gland Pharma but final hurdle remains

Fosun extends deadline to buy Gland Pharma but final hurdle remains

Ranjani R 4 months ago
China’s Shanghai Fosun Pharmaceutical (Group) Co. Ltd has extended the...
Fosun completes revised deal for 74% stake in Gland Pharma

Fosun completes revised deal for 74% stake in Gland Pharma

Ranjani R 2 months ago
Exclusive: India-China border tiff may derail $1.3 bn Fosun-Gland Pharma deal

Exclusive: India-China border tiff may derail $1.3 bn Fosun-Gland Pharma deal

Ranjani R 4 months ago
The biggest ever Chinese acquisition on Indian soil may flounder as a border...
No Comments

Gland Pharma looks to revise Fosun deal; Rosatom eyes Inox’s wind turbine biz

Powered by WordPress.com VIP